Get the latest tech news
An Experimental Obesity Pill Mimics Gastric Bypass Surgery
A novel drug that produces a temporary coating in the small intestine could be a new strategy for weight loss—and an alternative to surgeries and GLP-1 drugs.
“When nutrients are redirected to later in the intestine, you're activating pathways that lead towards satiety, energy expenditure, and overall healthy, sustainable weight loss,” Dhanda says. Louis Aronne, an obesity medicine specialist and professor of metabolic research at Weill-Cornell Medical College, says that while GLP-1s are wildly popular, they may not be right for everyone. Vladimir Kushnir, professor of medicine and director of bariatric endoscopy at Washington University in St. Louis, who isn’t involved with Syntis, says the early pilot data is encouraging, but it’s hard to draw any conclusions from such a small study.
Or read this on Wired